Stock listing
NASDAQ:CRSP CRISPR Therapeutics AG Stock
Home listing (NASDAQ) of CRISPR Therapeutics AG
Follow CRISPR Therapeutics AG into a list and get an email when it puts out news.
Share price · NASDAQ:CRSP
$39.10 USD -1.09 (-2.7%)
Close on Nov 20, 2026
- Day range
- $38.18 – $40.17 USDNov 20, 2026
- Volume
- 3.32M sharesNov 20, 2026
- Market cap
- $3.79B USDAt the close on Nov 20, 2026 · price × 97.00M shares outstanding
- 52-week range
- $38.18 – $63.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $89.03M USDMedian day 1.39M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRSP · Home | $39.10 USD | -1.09 (-2.7%) | 3,321,805 | $38.18 | $40.17 | $38.18 | $40.19 | Close on Nov 20, 2026 |
| LSE:0VRQ | $39.51 USD | +0.42 (+1.1%) | 8,682 | $38.60 | $40.23 | $38.11 | $39.09 | Close on Nov 20, 2026 |
| Frankfurt:1CG | €35.11 EUR | -1.38 (-3.8%) | — | €35.11 | €35.11 | €35.11 | €36.49 | Close on Nov 20, 2026 |
| B3:C2RS34 | 29.88 BRL | 0.00 (0.0%) | 3 | 29.88 | 29.88 | 29.88 | 29.88 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRSP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $39.10 | -1.09 | -2.7% | $38.18 | $40.17 | $38.18 | 3,321,805 | |
| $40.19 | +0.04 | +0.1% | $40.25 | $42.66 | $40.11 | 3,972,990 | |
| $40.15 | -0.22 | -0.5% | $40.19 | $41.17 | $39.80 | 4,108,033 | |
| $40.37 | -1.87 | -4.4% | $41.49 | $42.19 | $39.83 | 2,388,717 | |
| $42.24 | -0.38 | -0.9% | $42.50 | $42.79 | $41.79 | 1,872,766 | |
| $42.62 | -3.13 | -6.8% | $45.00 | $45.09 | $42.38 | 2,480,919 | |
| $45.75 | +0.60 | +1.3% | $45.98 | $46.31 | $44.50 | 2,674,156 | |
| $45.15 | -4.89 | -9.8% | $49.02 | $49.29 | $44.99 | 4,008,996 | |
| $50.04 | -0.03 | -0.1% | $50.57 | $51.52 | $48.71 | 1,058,136 | |
| $50.07 | +1.51 | +3.1% | $48.98 | $50.27 | $48.41 | 1,232,139 | |
| $48.56 | -3.215 | -6.2% | $51.01 | $51.21 | $47.76 | 2,142,260 | |
| $51.78 | +1.785 | +3.6% | $51.48 | $52.50 | $50.19 | 1,389,488 | |
| $49.99 | 0.00 | 0.0% | $50.26 | $51.86 | $49.62 | 1,287,859 | |
| $49.99 | -1.43 | -2.8% | $51.90 | $52.12 | $49.70 | 1,015,297 | |
| $51.42 | -2.84 | -5.2% | $53.27 | $54.10 | $50.60 | 1,166,454 | |
| $54.26 | +0.15 | +0.3% | $54.30 | $55.82 | $53.30 | 1,290,824 | |
| $54.11 | +2.64 | +5.1% | $50.48 | $54.17 | $50.10 | 1,125,973 | |
| $51.47 | +2.46 | +5.0% | $49.03 | $51.54 | $48.75 | 1,157,933 | |
| $49.01 | -0.38 | -0.8% | $49.36 | $50.11 | $48.65 | 1,065,670 | |
| $49.39 | -0.60 | -1.2% | $49.31 | $49.68 | $48.02 | 1,925,646 | |
| $49.99 | -0.51 | -1.0% | $50.14 | $51.05 | $49.36 | 906,106 | |
| $50.50 | +0.62 | +1.2% | $50.13 | $50.94 | $49.55 | 1,171,126 | |
| $49.88 | -0.16 | -0.3% | $48.87 | $50.33 | $47.36 | 2,156,437 | |
| $50.04 | +0.79 | +1.6% | $49.83 | $50.30 | $49.09 | 1,177,042 | |
| $49.25 | -2.27 | -4.4% | $51.20 | $51.36 | $49.05 | 1,518,000 | |
| $51.52 | +1.30 | +2.6% | $50.00 | $52.37 | $49.76 | 1,352,700 | |
| $50.22 | +0.12 | +0.2% | $49.67 | $50.78 | $48.91 | 1,703,000 | |
| $50.10 | -1.45 | -2.8% | $51.01 | $51.11 | $49.77 | 1,340,800 | |
| $51.55 | -1.84 | -3.4% | $52.91 | $53.21 | $51.40 | 1,103,600 | |
| $53.39 | +2.95 | +5.8% | $50.82 | $54.07 | $50.52 | 1,465,700 | |
| $50.44 | -1.91 | -3.6% | $51.51 | $53.54 | $50.02 | 2,863,400 | |
| $52.35 | -1.65 | -3.1% | $53.00 | $54.59 | $52.27 | 1,679,200 | |
| $54.00 | -3.34 | -5.8% | $60.39 | $60.68 | $53.74 | 2,622,800 | |
| $57.34 | +1.91 | +3.4% | $55.21 | $57.46 | $54.01 | 1,701,300 | |
| $55.43 | -0.01 | 0.0% | $56.45 | $57.58 | $54.09 | 1,128,300 | |
| $55.44 | +0.12 | +0.2% | $55.45 | $56.59 | $54.82 | 1,058,000 | |
| $55.32 | -0.68 | -1.2% | $56.55 | $57.11 | $55.28 | 1,165,000 | |
| $56.00 | +1.91 | +3.5% | $54.08 | $56.48 | $54.00 | 1,576,100 | |
| $54.09 | -0.14 | -0.3% | $53.84 | $55.63 | $52.90 | 1,269,700 | |
| $54.23 | -1.47 | -2.6% | $56.14 | $56.39 | $53.92 | 1,007,800 | |
| $55.70 | -0.06 | -0.1% | $54.95 | $57.17 | $53.79 | 1,554,900 | |
| $55.76 | -3.27 | -5.5% | $59.11 | $59.52 | $54.67 | 2,361,400 | |
| $59.03 | +0.70 | +1.2% | $58.73 | $60.72 | $57.64 | 2,080,800 | |
| $58.33 | +1.77 | +3.1% | $57.98 | $59.24 | $56.87 | 1,813,500 | |
| $56.56 | -0.765 | -1.3% | $58.00 | $59.34 | $55.63 | 3,382,000 | |
| $57.33 | +5.115 | +9.8% | $53.90 | $59.21 | $53.12 | 2,997,100 | |
| $52.21 | +0.38 | +0.7% | $52.16 | $53.67 | $51.83 | 2,663,300 | |
| $51.83 | -1.13 | -2.1% | $52.57 | $52.85 | $51.49 | 1,248,100 | |
| $52.96 | +1.24 | +2.4% | $51.33 | $53.80 | $51.33 | 1,523,700 | |
| $51.72 | -0.54 | -1.0% | $52.35 | $53.21 | $51.62 | 856,100 | |
| $52.26 | -1.19 | -2.2% | $52.50 | $52.63 | $51.72 | 1,261,400 | |
| $53.45 | -1.33 | -2.4% | $54.60 | $54.90 | $53.31 | 1,183,400 | |
| $54.78 | -1.01 | -1.8% | $54.45 | $55.10 | $52.78 | 1,385,500 | |
| $55.79 | -0.70 | -1.2% | $56.06 | $57.21 | $55.35 | 904,200 | |
| $56.49 | -0.43 | -0.8% | $57.50 | $57.80 | $55.72 | 1,487,700 | |
| $56.92 | +0.10 | +0.2% | $57.13 | $58.96 | $55.59 | 910,700 | |
| $56.82 | -0.16 | -0.3% | $56.22 | $57.13 | $55.43 | 890,500 | |
| $56.98 | -0.74 | -1.3% | $56.55 | $57.49 | $56.20 | 1,390,800 | |
| $57.72 | -1.65 | -2.8% | $58.22 | $59.37 | $57.10 | 1,386,300 | |
| $59.37 | +0.14 | +0.2% | $59.12 | $60.11 | $58.02 | 1,186,900 | |
| $59.23 | -1.67 | -2.7% | $60.18 | $60.39 | $58.06 | 953,400 | |
| $60.90 | +3.825 | +6.7% | $57.93 | $61.55 | $57.51 | 2,080,800 | |
| $57.08 | -2.425 | -4.1% | $58.75 | $58.96 | $56.62 | 1,118,600 | |
| $59.50 | +1.38 | +2.4% | $59.72 | $62.54 | $58.89 | 2,450,600 | |
| $58.12 | -1.69 | -2.8% | $58.73 | $60.90 | $56.94 | 2,910,400 |
Splits
1 split · NASDAQ:CRSP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 10-for-3 | Split |
- Ticker
- NASDAQ:CRSP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Latest deck · November 2026
Corporate Update (November 2026)
Corporate update · 40 slides
Latest news
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Nov 10, 2026
Closed $45.15 (-9.8%) on Nov 10, 2026
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
Nov 9, 2026
Closed $50.04 (-0.1%) on Nov 9, 2026
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Nov 8, 2026
Closed $50.04 (-0.1%) on Nov 9, 2026
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 4, 2026
Closed $51.78 (+3.6%) on Nov 4, 2026
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 2, 2026
Closed $49.99 (0.0%) on Nov 3, 2026
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
Nov 2, 2026
Closed $49.99 (-2.8%) on Nov 2, 2026
CRISPR Therapeutics Announces Chief Financial Officer Transition
Oct 19, 2026
Closed $49.88 (-0.3%) on Oct 20, 2026
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
Oct 8, 2026
Closed $50.44 (-3.6%) on Oct 8, 2026
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
Oct 2, 2026
Closed $55.43 (0.0%) on Oct 2, 2026
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 8, 2026
Closed $54.78 (-1.8%) on Sep 8, 2026
CRISPR Therapeutics AG on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 167 in all · newest Nov 10, 2026 · oldest 2019
- Decks
- 27 decks · latest November 2026
Where CRISPR Therapeutics AG is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRSP · Home listing · This page | NASDAQ | United States | USD |
| Tradegate:1CG | Tradegate | Germany | EUR |
| gettex:1CG | gettex | Germany | EUR |
| LS Exchange:A2AT0Z | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AT0Z | Lang & Schwarz | Germany | EUR |
| BOATS:CRSP | BOATS | United States | USD |
| LSE:0VRQ | LSE | United Kingdom | USD |
| Frankfurt:1CG | Frankfurt | Germany | EUR |
| BMV:CRSPN | BMV | Mexico | MXN |
| B3:C2RS34 | B3 | Brazil | BRL |
| BX Swiss:1CG | BX Swiss | Switzerland | CHF |
| BIVA:CRSPN | BIVA | Mexico | MXN |
| Hamburg:1CG | Hamburg | Germany | EUR |
| Munich:1CG | Munich | Germany | EUR |
| Dusseldorf:1CG | Dusseldorf | Germany | EUR |
| Stuttgart:1CG | Stuttgart | Germany | EUR |
| SET:CRSP03 | SET | Thailand | THB |
| Hanover:1CG | Hanover | Germany | EUR |
| Xetra:1CG | Xetra | Germany | EUR |
Valuation
EV/sales 83.7× against a median of 53.7×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.11B USD
- P/E
- Loss
- EV/sales
- 83.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.4×
- Beta vs S&P 500
- 1.64
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG · NASDAQ:CRSP | US$3.79B | US$2.11B | n/a | 83.7× | n/a | 2.3× | n/a | 0.4× | 1.64 |
| Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192 | US$3.90B | US$3.18B | 7.5× | 4.3× | n/a | 5.2× | 69.3% | 0.1× | n/a |
| Definium Therapeutics, Inc. · NASDAQ:DFTX | US$3.88B | US$2.87B | n/a | n/a | n/a | 4.0× | n/a | 0.0× | 1.14 |
| Tango Therapeutics, Inc. · NASDAQ:TNGX | US$3.68B | US$2.74B | n/a | n/a | n/a | 3.8× | n/a | 0.0× | 1.41 |
| Xenon Pharmaceuticals Inc. · NASDAQ:XENE | US$3.64B | US$2.70B | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 0.80 |
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.56B | US$3.42B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Median of the others | US$3.56B | US$2.74B | 7.6× | 53.7× | 4.0× | 69.6% | 0.0× | 1.00 |
Forecasts
9 strong buy · 4 buy · 10 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 85.42 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.53 · 19 analysts
- Revenue, year to Dec 2026
- 35.49M · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Samarth Kulkarni | Chief Executive Officer and Chairman of the Board |
| James R. Kasinger | General Counsel and Secretary |
| Megan Wherry Menner | Head of Human Resources |
| Naimish Patel | Chief Medical Officer |
| Siva Sakhamuri | Chief Technical Officer |
| Stephen Kennedy | Head of Technical Operations |
Board
| Director | Role |
|---|---|
| Samarth Kulkarni | Chief Executive Officer and Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · After close | 0.0% |
| Q2 2026 | Aug 3, 2026 · After close | +7.1% |
| Q1 2026 | May 4, 2026 · After close | −2.2% |
| Q4 2025 | Feb 12, 2026 · After close | +8.5% |
| Q3 2025 | Nov 10, 2025 · Before open | −1.0% |
| Q2 2025 | Aug 4, 2025 · After close | −6.7% |
| Q1 2025 | May 6, 2025 · After close | +3.3% |
| Q4 2024 | Feb 11, 2025 · After close | +9.3% |
| Q3 2024 | Nov 5, 2024 · Before open | −0.5% |
| Q2 2024 | Aug 5, 2024 · After close | −0.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +0.5% |
| Q4 2023 | Feb 21, 2024 · Before open | +4.7% |
| Q3 2023 | Nov 6, 2023 · After close | +13.6% |
| Q2 2023 | Aug 7, 2023 · After close | +9.7% |
| Q1 2023 | May 8, 2023 · After close | +13.3% |
| Q4 2022 | Feb 21, 2023 · After close | +8.0% |
| Q3 2022 | Nov 1, 2022 · After close | +5.1% |
| Q2 2022 | Aug 8, 2022 · Before open | −0.0% |
| Q1 2022 | May 9, 2022 · After close | +9.4% |
| Q4 2021 | Feb 15, 2022 · After close | +1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 40 slides | November 2026 |
| Q3 2026 Earnings Presentation | Earnings | 43 slides | Aug 3, 2026 |
| Corporate Update (February 2026) | Corporate update | 43 slides | Feb 12, 2026 |
| Investor Presentation (2025) | Investor deck | 38 slides | Nov 18, 2025 |
| Corporate Update (2025) | Corporate update | 33 slides | Aug 24, 2025 |
| Investor Presentation (July 2025) | Investor deck | 33 slides | July 2025 |
| Corporate Update (2024) | Corporate update | 26 slides | Nov 17, 2024 |
| Investor Presentation (August 2024) | Investor deck | 28 slides | August 2024 |
| Investor Presentation (May 2024) | Investor deck | 26 slides | May 2024 |
| Investor Presentation (March 2024) | Investor deck | 28 slides | March 2024 |
All 27 decks
IPO
Priced at US$14.00 a share on Oct 18, 2016.
- Price
- US$14.00 a share
- Shares offered
- 4,000,000 common shares
- Offering size
- US$56 million
- Underwriters' option
- Up to 600,000 more shares
- Underwriters
- Citigroup, Piper Jaffray, Barclays, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Oct 24, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 13, 2016 |
| Filed publicly | Sep 9, 2016 |
| Amended twice | Newest Oct 14, 2016 |
| Shares registered with an exchange | Oct 18, 2016 |
| Declared effective by the SEC | Oct 18, 2016 |
| Final prospectus, with the price | Oct 19, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 19, 2016 |
| EFFECT · Notice that a registration is effective | Oct 18, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Oct 18, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 18, 2016 |
| CORRESP · Letter to the SEC | Oct 14, 2016 |
| CORRESP · Letter to the SEC | Oct 14, 2016 |
| UPLOAD · Letter from the SEC | Oct 14, 2016 |
| S-1/A · Registration statement, amended | Oct 14, 2016 |
| S-1/A · Registration statement, amended | Oct 7, 2016 |
| CORRESP · Letter to the SEC | Sep 9, 2016 |
All 22 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Sep 9, 2016 |
| DRSLTR · Letter to the SEC with a draft | Sep 2, 2016 |
| UPLOAD · Letter from the SEC | Aug 26, 2016 |
| DRS/A · Draft registration statement, amended | Aug 19, 2016 |
| DRS/A · Draft registration statement, amended | Aug 12, 2016 |
| UPLOAD · Letter from the SEC | Aug 8, 2016 |
| DRS/A · Draft registration statement, amended | Jul 27, 2016 |
| UPLOAD · Letter from the SEC | Jul 18, 2016 |
| DRS/A · Draft registration statement, amended | Jul 8, 2016 |
| DRS/A · Draft registration statement, amended | Jun 29, 2016 |
| UPLOAD · Letter from the SEC | Jun 13, 2016 |
| DRS · Draft registration statement | May 13, 2016 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 19, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.51M | 37.3M | 371.2M | 1.20M | 915.0M | 719.0K | 289.6M | 3.12M | 41.0M | 5.16M |
| Research and development | 284.8M | 310.2M | 387.3M | 461.6M | 340.6M | 221.4M | 179.4M | 113.8M | 69.8M | 42.2M |
| Operating income | -664.6M | -466.6M | -222.5M | -673.2M | 373.5M | -354.4M | 46.7M | -158.9M | -64.6M | -68.1M |
| Depreciation and amortization | 19.5M | 19.3M | 19.8M | 24.2M | 18.0M | 9.18M | 4.72M | 3.52M | 3.02M | 925.0K |
| EBITDA | -645.1M | -447.3M | -202.7M | -649.0M | 391.5M | -345.3M | 51.5M | -155.4M | -61.6M | -67.2M |
| Income before tax | -578.0M | -362.7M | -150.7M | -650.5M | 379.5M | -348.1M | 67.3M | -164.4M | -66.6M | -22.7M |
| Income tax | 3.63M | 3.59M | 2.89M | -325.0K | 1.87M | 809.0K | 448.0K | 553.0K | 1.75M | 484.0K |
| Net income | -581.6M | -366.3M | -153.6M | -650.2M | 377.7M | -348.9M | 66.9M | -165.0M | -68.4M | -23.2M |
| Earnings per share, basic | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | -3.44 | -1.71 | -1.89 |
| Earnings per share, diluted | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | -3.44 | -1.71 | -1.89 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 347.6M | 298.3M | 389.5M | 211.9M | 923.0M | 1.17B | 943.8M | 456.6M | 239.8M | 315.5M |
| Short-term investments | 1.63B | 1.61B | 1.30B | 1.60B | 1.46B | 521.7M | 0 | |||
| Receivables | 0 | 25.0M | 200.0M | 0 | 305.0K | 144.0K | 99.0K | 88.0K | 2.63M | 3.16M |
| Current assets | 1.99B | 1.94B | 1.91B | 1.85B | 2.42B | 1.72B | 987.5M | 466.4M | 248.4M | 320.2M |
| Property, plant and equipment | 115.9M | 134.1M | 151.9M | 163.6M | 137.6M | 42.2M | 31.3M | 18.5M | 18.9M | 21.0M |
| Total assets | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B | 1.83B | 1.07B | 489.0M | 271.3M | 345.0M |
| Accounts payable | 11.1M | 14.7M | 38.1M | 27.4M | 14.8M | 9.09M | 5.94M | 5.07M | 1.64M | 4.57M |
| Current liabilities | 149.1M | 87.8M | 108.8M | 121.1M | 119.9M | 94.3M | 57.1M | 27.7M | 14.5M | 22.0M |
| Total debt | 0 | |||||||||
| Total liabilities | 343.4M | 310.0M | 346.8M | 367.6M | 352.4M | 163.7M | 127.3M | 96.8M | 83.5M | 112.1M |
| Shareholders' equity | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B | 1.66B | 939.4M | 392.2M | 187.8M | 232.8M |
| Shares outstanding | 95.9M | 85.7M | 80.0M | 78.5M | 77.0M | 73.9M | 60.8M | 51.9M | 40.6M | 39.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -345.0M | -142.8M | -260.4M | -495.7M | 539.0M | -238.4M | 56.7M | -96.2M | -70.1M | -52.9M |
| Capital spending | -914.0K | -1.90M | -9.47M | -37.2M | -81.7M | -18.4M | -6.68M | -2.77M | -7.81M | -3.02M |
| Free cash flow | -345.9M | -144.7M | -269.8M | -532.9M | 457.3M | -256.7M | 50.0M | -99.0M | -77.9M | -55.9M |
| Cash from investing | -31.8M | -280.5M | 374.6M | -258.7M | -1.04B | -541.2M | 1.32M | -2.77M | -8.31M | 31.9M |
| Cash from financing | 426.0M | 332.0M | 62.7M | 38.6M | 250.9M | 1.02B | 431.0M | 315.9M | 2.61M | 183.2M |
| Share buybacks | -57.0K | |||||||||
| Change in cash | 49.3M | -91.3M | 177.0M | -715.9M | -245.5M | 236.7M | 489.0M | 216.9M | -75.8M | 162.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 2, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 12, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2025 | Current report | SEC |
| 424B5 · Prospectus | Oct 15, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | May 19, 2025 | Offer document | SEC |
| 8-K · Current report | May 19, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 26, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 11, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 11, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| S-3ASR · Registration statement | Aug 5, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 30, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
This page holds 200 of 886 filings. Open Filings
Cap table
Built by 6ix from CRISPR Therapeutics AG’s releases
- Common shares
- 97,000,813
- Fully diluted
- 97,000,813
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 97,000,813 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 97,000,813 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Jun 11, 2019 |
| Briggs Morrison Other companies: Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 11, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past) | Director · Since at least Jun 5, 2025 |
| John Greene Other companies: Northrop Grumman Corporation (Corporate Vice President and Chief Financial Officer · Since at least Jan 7, 2026); Discover Financial Services (EVP, Chief Financial Officer · Sep 18, 2019 – May 18, 2025 · Past); Bioverativ Inc (EVP, CFO and Treasurer · Dec 22, 2016 – Mar 8, 2018 · Past); Willis Towers Watson Public Limited Company (Chief Financial Officer · Jun 2, 2014 – Nov 9, 2015 · Past) | Director · Since at least Jun 11, 2019 |
| Samarth Kulkarni Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); Black Diamond Therapeutics, Inc. (CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past) | Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016 |
| Simeon George Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2026); Design Therapeutics, Inc. (Director · Since at least Jun 15, 2022); Nkarta, Inc. (Director · Since at least Apr 28, 2022); Turning Point Therapeutics Inc (Director · Aug 17, 2022 – Aug 17, 2022 · Past) | Director · Since at least Jun 9, 2022 |
| Harold Edward Fleming Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Upstream Bio, Inc. (Director · Since at least Oct 10, 2024) | Director · Since at least Jun 10, 2021 |
| Brendan Smith Other companies: Translate Bio Inc (Chief Financial Officer · Apr 19, 2021 – Sep 14, 2021 · Past) | Chief Financial Officer · Oct 14, 2021 – Feb 18, 2023 · Past |
| Maria Fardis Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026) | Director · Since at least Jun 5, 2025 |
| Naimish Patel Other companies: AgomAb Therapeutics NV (Non-Executive Director · Since at least Sep 11, 2026) | Chief Medical Officer · Since at least Jun 1, 2026 |
| Christian Rommel | Director · Since at least May 30, 2024 |
All 17 people
| Person | Seat |
|---|---|
| James R. Kasinger | General Counsel and Secretary · Since at least Sep 10, 2019 |
| Megan Wherry Menner | Head of Human Resources · Since at least Nov 4, 2026 |
| Raju Prasad | Chief Financial Officer · Since at least Mar 14, 2023 |
| Rodger Novak | President, Director · Jun 10, 2019 – Jun 30, 2021 · Past |
| Siva Sakhamuri | Chief Technical Officer · Since at least Nov 2, 2026 |
| Stephen Kennedy | Head of Technical Operations · Since at least Nov 4, 2026 |
| Tyler Dylan-Hyde | Chief Legal Officer · Oct 18, 2016 – Jan 16, 2018 · Past |
Log in to ask 6ix AI your own questions about CRISPR Therapeutics AG.